Applies to the following strengths: 1 mg/mL
Usual Adult Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Rejection Reversal
5 mg IV once a day for 10-14 days.
Usual Adult Dose for Rejection Prophylaxis
5 mg IV once a day.
Usual Pediatric Dose for Rejection Reversal
< or = 30 kg: 2.5 mg IV once a day for 7-14 days.
> 30 kg: 5 mg IV once a day for 7-14 days.
Prior to administration, the patient should be evaluated for evidence of fluid overload and/or uncompensated heart failure. A weight gain of > 3% of the minimum weight during the week prior to injection has been associated with an increased incidence of rapid onset pulmonary edema following the first dose. The use of muromonab CD3 is considered contraindicated in such patients. A chest X-ray within 24 hours of the first dose is recommended and should be free of evidence of heart failure or fluid overload. Renal and hepatic function as well as CBC and differential should be monitored prior to and during therapy. Muromonab CD3 levels as determined by ELISA (>=800 ng/mL) or quantitative T lymphocyte surface phenotyping (< 25 CD3-positive cells/mm³) should be followed during therapy.
Muromonab CD3 is not dialyzable by most standard dialyzers. It may be dialyzed by high flux dialysis. It will be removed by plasmaphoresis. The dose should be administered following dialysis treatments.
Methylprednisilone sodium succinate 8 mg/kg IV 1-4 hours prior to and hydrocortisone sodium succinate 100 mg IV 30 minutes after administration is recommended to decrease the incidence and severity of the "first-dose reaction".
More about muromonab-cd3
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.